assessing safety and tolerability of mt-5111 in patients with her2 tumors
Published 2 years ago • 47 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
0:59
mt-5111: immunotoxin in her2 solid tumours
-
29:41
new approaches to assessing biocompatibility for medical devices
-
53:22
immunoregulation and t cell tolerance with arlene sharpe, md, phd
-
10:20
imaging 101: immunotherapy criteria
-
18:09
breast tumor-on-chip applicable for efficacy and safety assessment of car-t cell therapy
-
1:00:44
targeting cancer pathways: understanding immune checkpoints
-
44:56
immune checkpoint blockade in cancer therapy
-
22:52
haematological emergencies
-
1:46
dr. hofstatter on identifying high-risk patients in breast cancer
-
27:43
targeting the immune system with checkpoint inhibitors
-
48:48
what evidence do we need? – the promise of early treatment in cancer
-
1:50
dr lynce on ongoing trials evaluating novel combinations in inflammatory breast cancer
-
5:33
case 1: guidelines for her2 testing in breast cancer
-
7:13
evaluation of amg 420, an anti-bcma bispecific t-cell engager (bite) immunotherapy in patients w...
-
1:37
trials in progress presented at asco gi 2021
-
6:03
mrd-based risk assessment in multiple myeloma to inform maintenance discontinuation
-
1:36
nccn guidelines on molecular assays for patients with breast cancer
-
31:20
anat1010_27_lymphatic system
-
3:59
understanding risk in aml: how molecular testing affects treatment options
-
1:10
multicenter phase ii trial evaluates adapt-001 for resistant tumors, showing promising efficacy
-
![reliable analysis of antigen-specific t cells in immuno-oncology [webinar]](https://i.ytimg.com/vi/7-NNQ6GT_sg/mqdefault.jpg)
32:03
reliable analysis of antigen-specific t cells in immuno-oncology [webinar]
-
43:50
f. marangoni - analysis of nfat signaling dynamics in tumor-associated t cells..